← Back to Search

Hyperpolarized [13C] Pyruvate Injection for Fatty Liver Disease (HPFFF Trial)

Q: Does this investigation grant access to elderly persons?

To be eligible for this clinical trial, individuals must fall between 18 and 99 years old. There are additional trials available to those below 18 or over 65, with 22 studies dedicated to minors and 188 exclusively for seniors.

Q: Is my eligibility sufficient to join this trial?

To be eligible for this research, applicants must have fatty liver disease and fit within the age bracket of 18 to 99. An aggregate total of 16 people will be admitted into the trial.

Q: Are researchers looking to expand the patient pool for this trial?

Clinicaltrials.gov states that this particular medical experiment, which was initially listed on October 1st 2018, is not presently accepting participants. However, there are 228 other trials currently in progress and open to enrolment.

Phase < 1

Waitlist Available

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one visit of 6 hours; two injections of hp pyruvate with mri over 3 hours

Awards & highlights

HPFFF Trial Summary

This trial will test a new imaging agent to see if it can detect changes in the way the body breaks down fat in the liver.

HPFFF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one visit of 6 hours; two injections of hp pyruvate with mri over 3 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one visit of 6 hours; two injections of hp pyruvate with mri over 3 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and one visit of 6 hours; two injections of hp pyruvate with mri over 3 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Bicarbonate:lactate ratio

Secondary outcome measures

Labeled glycerol fraction

HPFFF Trial Design

2Treatment groups

Experimental Treatment

Group I: Healthy Control SubjectsExperimental Treatment1 Intervention

Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects

Group II: Fatty Liver PatientsExperimental Treatment1 Intervention

Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,048 Previous Clinical Trials

1,053,745 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this investigation grant access to elderly persons?

"To be eligible for this clinical trial, individuals must fall between 18 and 99 years old. There are additional trials available to those below 18 or over 65, with 22 studies dedicated to minors and 188 exclusively for seniors."

Answered by AI

Is my eligibility sufficient to join this trial?

"To be eligible for this research, applicants must have fatty liver disease and fit within the age bracket of 18 to 99. An aggregate total of 16 people will be admitted into the trial."

Answered by AI

Are researchers looking to expand the patient pool for this trial?

"Clinicaltrials.gov states that this particular medical experiment, which was initially listed on October 1st 2018, is not presently accepting participants. However, there are 228 other trials currently in progress and open to enrolment."

Answered by AI

Recent research and studies

in VivoJournal

in Vivohyperpolarized Carbon-13 Magnetic Resonance Spectroscopy Reveals Increased Pyruvate Carboxylase Flux in an Insulin-resistant Mouse Model

Lee, Philip, Waifook Leong, Trish Tan, Miangkee Lim, Weiping Han, and George K. Radda. 2013. “in Vivohyperpolarized Carbon-13 Magnetic Resonance Spectroscopy Reveals Increased Pyruvate Carboxylase Flux in an Insulin-resistant Mouse Model”. Hepatology. Wiley. doi:10.1002/hep.26028.

HepatologyJournal

Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference

Neuschwander-Tetri, B. 2003. “Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference”. Hepatology. Wiley. doi:10.1053/jhep.2003.50193.

Journal of Lipid ResearchJournal

Elevated TCA Cycle Function in the Pathology of Diet-induced Hepatic Insulin Resistance and Fatty Liver

Satapati, Santhosh, Nishanth E. Sunny, Blanka Kucejova, Xiaorong Fu, Tian Teng He, Andrés Méndez-Lucas, John M. Shelton, Jose C. Perales, Jeffrey D. Browning, and Shawn C. Burgess. 2012. “Elevated TCA Cycle Function in the Pathology of Diet-induced Hepatic Insulin Resistance and Fatty Liver”. Journal of Lipid Research. Elsevier BV. doi:10.1194/jlr.m023382.

Journal of Biological ChemistryJournal